Iroquois Capital Discloses 282,952 Share Stake in Clearmind Medicine

TL;DR

**Hedge fund Iroquois Capital just bought a big chunk of Clearmind Medicine, signaling a potential bullish outlook.**

AI Summary

Iroquois Capital Management, LLC, a Delaware-based investment firm, has disclosed a significant stake in Clearmind Medicine Inc., a pharmaceutical company. As of January 11, 2024, Iroquois Capital beneficially owns 125,000 shares of common stock with shared voting power and an additional 157,952 shares of common stock issuable upon exercise of warrants, totaling 282,952 shares. This filing indicates a notable investment by a hedge fund, suggesting potential confidence in Clearmind Medicine's future, which could be a positive signal for current and prospective shareholders.

Why It Matters

This filing reveals a hedge fund's substantial investment in Clearmind Medicine, which could signal institutional confidence and potentially influence the stock's perception and future performance.

Risk Assessment

Risk Level: low — This filing indicates a new institutional investment, which is generally seen as a positive development and does not inherently increase risk.

Analyst Insight

A smart investor would view this institutional investment as a potential vote of confidence, prompting further research into Clearmind Medicine's fundamentals and future prospects, especially given the pharmaceutical sector's volatility.

Key Numbers

• 125,000 shares — Common Stock (Shared Voting Power) (Directly owned shares by Iroquois Capital Management, LLC)
• 157,952 shares — Common Stock (Issuable upon Warrants) (Potential additional shares Iroquois Capital Management, LLC could own)
• 282,952 shares — Total Beneficially Owned Shares (Combined direct and potential shares held by Iroquois Capital Management, LLC)

Key Players & Entities

• Iroquois Capital Management, LLC (company) — reporting person, investment firm
• Clearmind Medicine Inc. (company) — subject company, pharmaceutical preparations
• 125,000 shares (dollar_amount) — common stock with shared voting power
• 157,952 shares (dollar_amount) — common stock issuable upon exercise of warrants
• January 11, 2024 (date) — date of event requiring filing
• Delaware (company) — place of organization for Iroquois Capital Management, LLC

Forward-Looking Statements

• Clearmind Medicine Inc.'s stock price may see increased investor interest due to institutional backing. (Clearmind Medicine Inc.) — medium confidence, target: Q1 2024
• Iroquois Capital Management, LLC may increase its stake in Clearmind Medicine Inc. if the company's performance aligns with their investment thesis. (Iroquois Capital Management, LLC) — low confidence, target: Q2 2024

FAQ

Filing Documents

• c107818_sc13g.htm (SC 13G) — 51KB
• 0000930413-24-000267.txt ( ) — 53KB

(a)

Item 2 (a). Name of Person Filing

(b)

Item 2 (b). Address of Principal Business Office or, if none, Residence

(c)

Item 2 (c). Citizenship This Schedule 13G is being filed on behalf of (i) Iroquois Capital Management L.L.C., a Delaware limited liability company (“Iroquois”), (ii) Richard Abbe, an individual who is a citizen of the United States of America and (iii) Kimberly Page, an individual who is a citizen of the United The Reporting Persons have entered into a Joint Filing Agreement, a copy of which is filed with this Schedule 13G as Exhibit 1, pursuant to which the Reporting Persons have agreed to file this Schedule 13G jointly in accordance with the provisions of Rule 13d-1(k) of the Securities Exchange Act of 1934, as amended. The principal business office of all of the Reporting Persons is 2 Overhill Road, Scarsdale, New York 10583.

(d)

Item 2 (d) Title of Class of Securities Common Stock, no par value

(e)

Item 2 (e) CUSIP Number Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: Not applicable. (a) Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o). (b) Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c). (c) Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c). (d) Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8). (e) An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E); (f) An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F); (g) A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G); (h) A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); (i) A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); (j) A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J); (k) Group, in accordance with Rule 13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution: Item 4. Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. The information as of the date of the event which requires filing of this statement required by Items 4(a) – (c) is set forth in Rows 5 – 11 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person. The percentage set forth in Row 11 of the cover page for each Reporting Person is based on 3,169,570 shares of Common Stock issued and outstanding as represented in the Company’s Prospectus Supplement filed

SIGNATURES

SIGNATURES After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date: January 22, 2024 IROQUOIS CAPITAL MANAGEMENT L.L.C. By: /s/ Richard Abbe Richard Abbe, President /s/ Richard Abbe Richard Abbe /s/ Kimberly Page Kimberly Page EXHIBIT INDEX Exhibit 1 Joint Filing Agreement as required by Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended. Exhibit 1 JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k)(1) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him, her or it contained herein, but shall not be responsible for the completeness and accuracy of the information concerning the other entities or persons, except to the extent that he, she or it knows or has reason to believe that such information is inaccurate. Date: January 22, 2024 IROQUOIS CAPITAL MANAGEMENT L.L.C. By: /s/ Richard Abbe Richard Abbe, President /s/ Richard Abbe Richard Abbe /s/ Kimberly Page Kimberly Page

View Full Filing

View this SC 13G filing on SEC EDGAR